Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

83.01 -1.41 (-1.67%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Understanding Merck &amp; Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
3 Under-The-Radar Stocks With Positive Potential
Via Talk Markets
Unveiling 17 Analyst Insights On Merck & Co
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue. 
Via InvestorPlace
Exposures Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Understanding Merck &amp; Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
These dividends are about as safe as they come. 
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Being able to stop a drug's unwanted effects could lead to a larger market share. 
Via The Motley Fool
1 New Green Flag for Moderna and Merck Stock
There's a new reason to believe that their joint projects are going well. 
Via The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government... 
Via Benzinga
Exposures COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response... 
Via Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
A popular and rewarding goal in investing is building a strong portfolio for retirement. These retirement stocks should help. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April. 
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a... 
Via Benzinga
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
From Daiichi Sankyo
Via Business Wire
Forget Shopify: This Stock Has Made Far More Millionaires
It's a reliable winner with plenty more room to run. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.